Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study

The results from the largest, pan-European, real-life study on irinotecan-TACE for CRLMs show a comparably long median OS when used as salvage therapy and promising HPFS when used with systemic therapy or thermal ablation as post-inductive/consolidation therapy. With its potential to maintain HRQoL, irinotecan-TACE could be further integrated into systemic treatment pathways.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-02-15
DOI
https://doi.org/10.1016/j.esmoop.2025.104292
Citations
4
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
5.29
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study

Thierry de Baère, Dirk Arnold, Philippe L. Pereira, Julien Taı̈eb et al.
4 citations
ESMO Open
Hepatocellular Carcinoma Treatment and Prognosis
5.29
article

Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study

Thierry de Baère, Dirk Arnold, Philippe L. Pereira, Julien Taı̈eb, Bleranda Zeka, Thomas Helmberger, Roberto Iezzi, Olivier Pellerin, Hans Prenen, Nathalie Kaufmann, Stavros Spiliοpoulos, Fernando Gómez, Geert Maleux, Bruno Sangro, A. Gjoreski
article en
4 citations

Abstract

The results from the largest, pan-European, real-life study on irinotecan-TACE for CRLMs show a comparably long median OS when used as salvage therapy and promising HPFS when used with systemic therapy or thermal ablation as post-inductive/consolidation therapy. With its potential to maintain HRQoL, irinotecan-TACE could be further integrated into systemic treatment pathways.

ESMO OpenVol. 10(3)
Délégation Paris 5 (FR), National and Kapodistrian University of Athens (GR), Université Paris Cité (FR), Universitair Ziekenhuis Leuven (BE), Institut Gustave Roussy (FR), Agostino Gemelli University Polyclinic (IT), München Klinik Bogenhausen (DE), Asklepios Klinik Altona (DE), Antwerp University Hospital (BE), Hôpital Européen Georges-Pompidou (FR), Centro de Investigación Biomédica en Red (ES), Hospital Clínic de Barcelona (ES), Clinica Universidad de Navarra (ES), PHI University Psychiatric Clinic - Skopje (MK), SLK-Kliniken Heilbronn (DE), Cardiovascular and Interventional Radiological Society of Europe (AT), Catholic University of America (US)
Openalex Percentile: Top 5%
Hepatocellular Carcinoma Treatment and Prognosis
5.29
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.